- Home
- NUVL vs CIG Comparison
NUVL vs CIG Comparison
Compare NUVL & CIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- CIG
- Stock Information
- Founded
- NUVL 2017
- CIG 1952
- Country
- NUVL United States
- CIG Brazil
- Employees
- NUVL N/A
- CIG N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- CIG Electric Utilities: Central
- Sector
- NUVL Health Care
- CIG Utilities
- Exchange
- NUVL Nasdaq
- CIG Nasdaq
- Market Cap
- NUVL 5.6B
- CIG 4.9B
- IPO Year
- NUVL 2021
- CIG N/A
- Fundamental
- Price
- NUVL $73.48
- CIG $1.89
- Analyst Decision
- NUVL Strong Buy
- CIG
- Analyst Count
- NUVL 8
- CIG 0
- Target Price
- NUVL $115.50
- CIG N/A
- AVG Volume (30 Days)
- NUVL 682.1K
- CIG 3.3M
- Earning Date
- NUVL 05-08-2025
- CIG 05-09-2025
- Dividend Yield
- NUVL N/A
- CIG 10.84%
- EPS Growth
- NUVL N/A
- CIG 60.51
- EPS
- NUVL N/A
- CIG 0.40
- Revenue
- NUVL N/A
- CIG $6,438,199,502.00
- Revenue This Year
- NUVL N/A
- CIG N/A
- Revenue Next Year
- NUVL N/A
- CIG $4.76
- P/E Ratio
- NUVL N/A
- CIG $5.28
- Revenue Growth
- NUVL N/A
- CIG 8.06
- 52 Week Low
- NUVL $55.54
- CIG $1.59
- 52 Week High
- NUVL $113.51
- CIG $2.19
- Technical
- Relative Strength Index (RSI)
- NUVL 54.91
- CIG 60.70
- Support Level
- NUVL $71.60
- CIG $1.69
- Resistance Level
- NUVL $74.28
- CIG $1.72
- Average True Range (ATR)
- NUVL 4.86
- CIG 0.05
- MACD
- NUVL 1.08
- CIG 0.02
- Stochastic Oscillator
- NUVL 95.73
- CIG 96.43
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About CIG Comp En De Mn Cemig ADS
Cia Energetica DE Minas Gerais - Cemig Formerly Energy Company of Minas Gerais is a Brazilian power company that generates, transmits, and distributes electricity. As one of the largest power companies in Brazil, the firm operates across most Brazilian states and Chile. The company has various subsidiaries and operates chiefly through its generation, transmission, distribution, and gas segments. The majority of the company's revenue is derived from electricity sales to consumers. The company generates power primarily through hydroelectric resources and secondarily through thermal and wind resources.